Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant immunotherapy combined with HAIC-FOLFOX for high-risk resectable gallbladder carcinoma
ChiCTR2600134729Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, oxaliplatin, fluorouracil and folinic acid in gallbladder cancer and biliary cancer, sponsored by Shandong Cancer Hospital. Primary endpoint: Event-free survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
durvalumaboxaliplatinfluorouracilfolinic acid
03
Conditions
gallbladder cancerbiliary cancer
Beyond the preview
Go deeper on ChiCTR2600134729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134729.